NVP-BHG712 alleviates ovariectomy-induced osteoporosis by modulating osteoclastogenesis

Postmenopausal osteoporosis (PMOP) is closely related to the pathogenesis of osteoclasts, with the Cathepsin K (CTSK) protein playing a crucial role. Our study aimed to screen small molecule compounds targeting CTSK and evaluate their impact on PMOP. Through molecular docking, we identified NVP-BHG712 as significantly inhibiting osteoclast differentiation and bone resorption. NVP-BHG712 also effectively suppressed CTSK activity and exhibited strong binding affinity to CTSK protein. Furthermore, NVP-BHG712 regulated the expression of inflammatory factors and modulated the balance between M1 and M2 macrophage polarization. In the mouse model of ovariectomy-induced osteoporosis, NVP-BHG712 rescued bone loss by inhibiting excessive osteoclast activation. These findings suggest that NVP-BHG712 may be a promising treatment for pathological osteoporosis by alleviating osteoclast function.

Authors

Institutions

Publication Details

Journal
European Journal of Pharmacology
Published
2024-09-13
DOI
https://doi.org/10.1016/j.ejphar.2024.177000
Citations
2
Primary Topic
Bone Metabolism and Diseases
Type
article
Field-Weighted Citation Impact
0.47
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

NVP-BHG712 alleviates ovariectomy-induced osteoporosis by modulating osteoclastogenesis

Wendi Chen, Yongzhi Cao, Yunna Ning, Huanxin Sun et al.
2 citations
European Journal of Pharmacology
Bone Metabolism and Diseases
0.47
article

NVP-BHG712 alleviates ovariectomy-induced osteoporosis by modulating osteoclastogenesis

Wendi Chen, Yongzhi Cao, Yunna Ning, Huanxin Sun, Gang Lü, Guolong Wang, Shuang Liu, Ming Li, Xin Liu, Yueran Zhao, Jing Zhang, Yuxuan Shi
article en
2 citations

Abstract

Postmenopausal osteoporosis (PMOP) is closely related to the pathogenesis of osteoclasts, with the Cathepsin K (CTSK) protein playing a crucial role. Our study aimed to screen small molecule compounds targeting CTSK and evaluate their impact on PMOP. Through molecular docking, we identified NVP-BHG712 as significantly inhibiting osteoclast differentiation and bone resorption. NVP-BHG712 also effectively suppressed CTSK activity and exhibited strong binding affinity to CTSK protein. Furthermore, NVP-BHG712 regulated the expression of inflammatory factors and modulated the balance between M1 and M2 macrophage polarization. In the mouse model of ovariectomy-induced osteoporosis, NVP-BHG712 rescued bone loss by inhibiting excessive osteoclast activation. These findings suggest that NVP-BHG712 may be a promising treatment for pathological osteoporosis by alleviating osteoclast function.

European Journal of PharmacologyVol. 983
Shandong University (CN), Chinese University of Hong Kong (HK), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Shandong First Medical University (CN)
Zero hunger
Openalex Percentile: Top 35%
Bone Metabolism and Diseases
0.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

NVP-BHG712 alleviates ovariectomy-induced osteoporosis by modulating osteoclastogenesis — Wendi Chen, Yongzhi Cao, et al. · European Journal of Pharmacology (2024) | TGRS Research Map | TGRS